PFIZER INC — Director's Dealing 2021

Dec 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2021-12-17

Reporting Person: Dolsten Mikael (President R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-17	Common Stock	M	71187.0000	$30.1700	Acquired	351637.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-17	Phantom Stock Units	$	I	25219.0000	Disposed		Common Stock (25219.0000)	Direct
2021-12-17	Stock Appreciation Rights	$30.1700	M	152085.0000	Disposed	2023-02-22	Common Stock (152085.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1802.0000	Indirect

Footnotes

F1: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.

F2: Each unit represents one phantom share of common stock.

F3: The reporting person diversified shares held in the Pfizer Inc. Deferred Compensation Plan (Plan) pursuant to the Plan's diversification provision into an alternate investment option(s) under the Plan.

F4: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.